Internal and Emergency Medicine

, Volume 12, Issue 1, pp 1–7 | Cite as

Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome

  • Savino SciasciaEmail author
  • Massimo Radin
  • Mario Bazzan
  • Dario Roccatello


The anti-phospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity, associated with a persistent positivity for anti-phospholipid antibodies (aPL). The current classification criteria for APS include three laboratory tests: lupus anti-coagulant (LA), anti-cardiolipin (aCL), and anti-β2 glycoprotein-I (β2GPI). To date, the therapeutic approach for thrombotic APS mainly centers on long-term anti-coagulation with a vitamin K antagonist (VKA). APS management may represent a challenge for the treating physicians. Patients with different aPL profiles need a tailored risk-stratified approach. Moreover, in patients with recurrent thrombotic events despite therapy with VKA, or in those with microvascular involvement, new therapeutic options are highly needed. In this review, we aim to elucidate recent findings about new aPL specifities, available risk scoring models, and novel therapeutic approaches in APS management.


APS Thrombosis Pregnancy morbidity aPL 


Compliance with ethical standards

Conflict of interest

The Authors declare that they have no conflict of interest.

Statement of human and animal rights

Not applicable.

Informed consent

Not applicable.


None declared.


  1. 1.
    Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306CrossRefPubMedGoogle Scholar
  2. 2.
    Mahler M, Norman GL, Meroni PL, Khamashta M (2012) Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 12(2):313–317CrossRefPubMedGoogle Scholar
  3. 3.
    Radin M, Cecchi I, Roccatello D et al (2016) Prevalence and thrombotic risk assessment of anti-domain I beta 2 glycoprotein I antibodies: a systematic review and a meta-analysis. Lupus 25 (abstract supplement 1S)Google Scholar
  4. 4.
    Sciascia S, Khamashta MA, Bertolaccini ML (2014) New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Curr Rheumatol Rep 16(5)Google Scholar
  5. 5.
    Ruffatti A, Del Ross T, Ciprian M et al (2011) Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 70(6):1083–1086CrossRefPubMedGoogle Scholar
  6. 6.
    Galli M, Luciani D, Bertolini G et al (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101(5):1827–1832CrossRefPubMedGoogle Scholar
  7. 7.
    Groot PGDE, Lutters B, Derksen RHWM, Lisman T (2005) Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. 1993–1997Google Scholar
  8. 8.
    Pengo V, Ruffatti A, Legnani C et al (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8(2):237–242CrossRefPubMedGoogle Scholar
  9. 9.
    Otomo K et al (2012) Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64(2):504–512CrossRefPubMedGoogle Scholar
  10. 10.
    Sciascia S, Sanna G, Murru V et al (2013) GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford) 52(8):1397–1403CrossRefGoogle Scholar
  11. 11.
    Sciascia S, Baldovino S, Schreiber K et al (2016) Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. Clin Mol Allergy 14(1):6CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sciascia S, Khamashta MA, D’Cruz DP (2014) Targeted therapy in antiphospholipid syndrome. Curr Opin Rheumatol 26(3):269–275Google Scholar
  13. 13.
    Rand JH, Wu X-X, Quinn AS et al (2010) Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115(11):2292–2299CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kaiser R, Cleveland CM, Criswell LA (2009) Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 68(2):238–241CrossRefPubMedGoogle Scholar
  15. 15.
    Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR et al (2016) Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 3(9):e426–e436CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sciascia S, Giachino O, Roccatello D Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol 30(3):409–413Google Scholar
  17. 17.
    Erre GL, Pardini S, Faedda R, Passiu G (2008) Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 17(1):50–55CrossRefPubMedGoogle Scholar
  18. 18.
    Sciascia S, Naretto C, Rossi D, Bazzan M, Roccatello D (2011) Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus 20(10):1106–1108CrossRefPubMedGoogle Scholar
  19. 19.
    Durcan L, Fu W, Petri M (2016) Hypocomplementemia associates with thrombosis in SLE patients with antiphospholipid antibodies. Ann Rheum Dis 75(Suppl2):126Google Scholar
  20. 20.
    Pengo V, Ruffatti A, Legnani C et al (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8(2):237–242Google Scholar

Copyright information

© SIMI 2017

Authors and Affiliations

  • Savino Sciascia
    • 1
    • 2
    Email author
  • Massimo Radin
    • 1
  • Mario Bazzan
    • 3
  • Dario Roccatello
    • 1
    • 2
  1. 1.Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d’Aosta Network for Rare DiseasesS. Giovanni Bosco HospitalTurinItaly
  2. 2.SCDU Nephrology and DialysisS. Giovanni Bosco HospitalTurinItaly
  3. 3.UOSD Hematology and Thrombosis UnitS. Giovanni Bosco HospitalTurinItaly

Personalised recommendations